
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is positioned for revenue growth through 2030, bolstered by the acquisition of Lumryz, which is anticipated to contribute approximately $265-$275 million in annualized sales by 2025, with further growth expected in the subsequent years, particularly in the narcolepsy and idiopathic hypersomnia markets. The company's ongoing investments in its innovative product pipeline, including alixorexton, are expected to enhance earnings per share while supporting essential Phase III development programs. Overall, the acquisition of Lumryz presents a strategic opportunity that strengthens Alkermes's commercial operations and reinforces its financial outlook without excessively burdening its balance sheet.
Bears say
Alkermes PLC faces a negative outlook primarily due to potential sales declines and competitive pressures affecting its key product, Lumryz, which is projected to peak at approximately $600 million by 2030 before experiencing annual declines coinciding with patent expirations and increased competition from other OX2R agonists. Additionally, significant risks surround the company's reliance on its royalty business and early-stage orexin data, which requires further validation, while potential erosion of market share for oxybates could hinder overall growth in the narcolepsy market. Finally, a downward adjustment in the EBITDA multiple reflects a more cautious assessment of the company's future cash flows, indicating concerns over the sustainability of its growth trajectory in light of emerging competition and existing market dynamics.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares